根据香港法例第571W章证券及期货(稳定价格)规则第9(2)条，公司宣布，有关全球发售的稳定价格期已 于2025年12月24日(星期三)(即提交香港公开发售申请的截止日期后第30日)结束。 量化派(02685)发布公告，整体协调人已于2025年12月24日(星期三)部分行使招股章程所述的超额配股 权，涉及合共175万股股份，占于任何超额配股权获行使前全球发售项下初步可供认购发售股份总数约 13.11%。超额配发股份将由公司按每股股份9.80港元予以发行及配发。超额配发股份将用于促进向Mars Legend Limited交还根据借股协议所借入用于补足国际发售项下超额分配的175万股股份。 ...

根据香港法例第571W章证券及期货(稳定价格)规则第9(2)条，公司宣布，有关全球发售的稳定价格期已 于2025年12月24日(星期三)(即提交香港公开发售申请的截止日期后第30日)结束。 超额配发股份将由公司按每股股份9.80港元(不包括1.0%经纪佣金、0.0027%证监会交易徵费、0.00015% 会财局交易徵费及0.00565%联交所交易费)(即全球发售项下每股股份的发售价)予以发行及配发。超额 配发股份将用于促进向Mars Legend Limited交还根据借股协议所借入用于补足国际发售项下超额分配的 1,750,000股股份。 格隆汇12月24日丨量化派(02685.HK)公告，公司宣布，整体协调人(为其本身及代表国际包销商)已于 2025年12月24日(星期三)部分行使招股章程所述的超额配股权，涉及合共1,750,000股股份，占于任何超 额配股权获行使前全球发售项下初步可供认购发售股份总数约13.11%。 ...

乐舒适(02698)发布公告，招股章程所述的超额配股权已于2025年12月5日由整体协调人(为彼等本身及代 表国际包销商)悉数行使，涉及合共1363.26万股股份，相当于超额配股权获行使前全球发售项下初步可 供提呈发售的发售股份总数约15%。超额配发股份将由公司按每股26.20港元(即全球发售项下每股发售 价)予以发行及配发。此外，有关全球发售的稳定价格期已于2025年12月5日(即提交香港公开发售申请 的截止日期后第30日)结束。 ...

均胜电子（600699）(00699)发布公告，有关全球发售的稳定价格期于2025年12月3日(即递交香港公开发 售申请截止日期后的第30日)结束。中国国际金融香港证券有限公司(作为稳定价格操作人)、其联属人士 或代其行事的任何人士于稳定价格期采取的稳定价格行动载于本公告。此外，整体协调人(为其本身及 代表国际承销商)于价格稳定期并无行使超额配股权，超额配股权于2025年12月3日失效。因此，并无H 股根据超额配股权发行或将予发行。 ...

Core Insights - Minglue Technology-W (02718) announced that the overallotment option described in the prospectus was fully exercised by the sole sponsor and global coordinator on November 27, 2025, involving a total of 1.0828 million Class A shares, which represents approximately 15% of the total shares initially available for subscription under the global offering [1] - The shares from the overallotment option will be issued at a price of HKD 141.00 per share [1] - The overallotment shares will be used to facilitate the delivery of a portion of the shares to cornerstone investors who have agreed to delay the delivery of their subscribed shares under the global offering [1] - The stabilization period for the global offering ended on November 27, 2025, which is the 30th day after the submission of the public offering application in Hong Kong [1]

Core Insights - The company, Jinfang Pharmaceutical-B (02595), announced that the sole sponsor and overall coordinator has fully exercised the over-allotment option as of October 16, 2025, involving a total of 13.386 million H-shares, which represents approximately 15% of the total shares available for subscription before the exercise of any over-allotment options [1] - The over-allotment shares will be issued at a price of HKD 20.39 per H-share and will be used to cover the excess allocation in the international offering [1] - The stabilization period for the global offering ended on October 16, 2025, which is 30 days after the submission deadline for the Hong Kong public offering application [1]

Core Viewpoint - The announcement indicates that the stabilization period for the global offering of Xunzhong Communication (02597) ended on August 3, 2025, with no over-allotment of H-shares during the international offering [1] Group 1 - The stabilization period concluded 30 days after the deadline for submitting the application for the Hong Kong public offering [1] - The overall coordinator did not exercise the over-allotment option due to the absence of excess allocation of H-shares [1] - No stabilization actions were taken during the stabilization period by the stabilization agent or any associated parties [1] Group 2 - The over-allotment option expired on August 3, 2025, meaning the company will not issue H-shares under this option [1]

Core Viewpoint - The company announced the end of the stabilization period for its global offering, which will conclude on August 3, 2025, marking the 30th day from the deadline for submitting applications for the Hong Kong public offering [1] Group 1 - The stabilization period is governed by the Securities and Futures (Stabilizing Prices) Rules under Hong Kong law [1] - The stabilization actions will be conducted by China International Capital Corporation Hong Kong Securities Limited or its affiliates [1]

Group 1 - The company, FWD Group (01828), announced that the over-allotment option described in the prospectus has been partially exercised by the joint global coordinators on August 1, 2025, involving a total of 5.0014 million shares, which is approximately 5.48% of the total number of shares initially available for subscription before the exercise of any over-allotment option [1] - The over-allotment shares will be issued and allocated by the company at a price of HKD 38.00 per share [1] - The over-allotment shares will be used to facilitate the partial repayment to the stabilizing agent, Morgan Stanley Asia Limited or its affiliates, for shares borrowed under a stock borrowing agreement to cover the over-allocation of 13.7013 million shares in the international offering [1] - The stabilization period for the global offering ended on August 1, 2025 [1]